Arch-Clamping Technique Under Mild Hypothermia in Treating With Acute Type A Aortic Dissection
AHEAD
1 other identifier
interventional
306
1 country
1
Brief Summary
The study is a multicenter, three-arm, open-label, randomized, parallel-controlled trial, which plans to enroll 306 participants diagnosed with acute type A aortic dissection (ATAAD) from 7 hospitals in China. All patients receive total arch replacement (TAR) combined with frozen elephant trunk (FET) implantation and are randomized to Group 1 (arch-clamping technique under mild hypothermia), Group 2 (arch-clamping technique under moderate hypothermia) and Group 3 (Sun's procedure using bilateral antegrade cerebral perfusion) in the ratio of 1:1:1. After a 1-year follow-up, the validity and safety of the mild hypothermic arch-clamping technique for ATAAD was evaluated via the incidence of major adverse events including death, renal replacement therapy, stroke, and paraplegia, as well as times of circulatory arrest, cardiopulmonary bypass, and mechanical ventilation, and length of ICU stay.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Feb 2026
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 25, 2025
CompletedFirst Posted
Study publicly available on registry
September 2, 2025
CompletedStudy Start
First participant enrolled
February 1, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 30, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
February 28, 2028
December 15, 2025
September 1, 2025
1.9 years
August 25, 2025
December 7, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Major adverse events
Major adverse events include death, renal replacement therapy, stroke, and paraplegia
Thirty days and 12 months after the operation
Secondary Outcomes (4)
Circulatory arrest time
During surgery
Cardiopulmonary bypass time
During surgery
Mechanical ventilation time
Discharge / 30 days after operation
The length of ICU stay
Discharge / 30 days after operation
Study Arms (3)
Arch-clamping under mild hypothermia
EXPERIMENTALTAR + FET procedure is performed using arch-clamping technique under mild hypothermia.
Arch-clamping under moderate hypothermia
EXPERIMENTALTAR + FET procedure is performed using arch-clamping technique under moderate hypothermia.
Sun's procedure using bACP
ACTIVE COMPARATORTotal arch replacement and frozen elephant trunk implantation with moderate hypothermic circulatory arrest.
Interventions
This procedure is performed under moderate hypothermia. The branch arteries of the arch are reconstructed using the side arms of a Y-shaped graft, which allow bACP through the right axillary artery. A FET is deployed in the descending aorta and clamped together with the autologous aorta immediately, then distal perfusion is restored through the femoral artery. After the proximal procedures are completed, the distal anastomosis is performed in an end-to-end fashion. Finally, the main trunk of the Y-shaped graft is anastomosed to the proximal grafts.
This procedure is performed under mild hypothermia. The branch arteries of the arch are reconstructed using the side arms of a Y-shaped graft, which allows bilateral antegrade cerebral perfusion (bACP) through the right axillary artery. A FET is deployed in the descending aorta and clamped together with the autologous aorta immediately, then distal perfusion is restored through the femoral artery. After the proximal procedures are completed, the distal anastomosis is performed in an end-to-end fashion. Finally, the main trunk of the Y-shaped graft is anastomosed to the proximal grafts.
This procedure is performed using bACP under MHCA, which involves FET deployment in the descending aorta followed by total arch replacement with a four-branched vascular graft. Deployment of the FET and suture of the distal anastomosis are completed during bACP. MHCA is terminated and distal reperfusion is initiated once the distal anastomosis is completed, and the left carotid artery is reconstructed first (after which bACP is stopped, rewarming is started and the brain is perfused bilaterally). The root or valve procedures and some concomitant operations, if indicated, are performed during the cooling phase.
Eligibility Criteria
You may qualify if:
- Aortic CTA confirmed as ATAAD according to the 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease;
- Adult patients (18-70 years) weighing 50-120 kg;
- Time interval between the onset of symptoms and operation is less than 14 days;
- Indications for total aortic arch replacement are available;
- Signed informed consent and availability for follow-up.
You may not qualify if:
- History of chronic renal failure, hepatocirrhosis, and hepatic insufficiency;
- Severe gastrointestinal complications of non-aortic dissection, such as mesenteric ischemia, gastrointestinal bleeding, hepatopancreaticobiliary dysfunction, and intestinal obstruction;
- History of severe cerebral infarction (with cerebral infarction sequels);
- Preoperative intubation or unconsciousness;
- Inflammatory aortic diseases, such as Takayasu arteritis and Behçet's disease, etc;
- History of infectious aortic diseases;
- History of cardiac and aortic surgery;
- History of malignancy or previous radiotherapy;
- Pregnant or feeding women, or anyone planning to reproduce during the test period;
- Without an informed consent signature;
- Participating in any other clinical trial;
- Having other causes not eligible for operation.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Yan'an Affiliated Hospital of Kunming Medical Universitycollaborator
- Beijing Anzhen Hospitallead
- Xiangya Hospital of Central South Universitycollaborator
- West China Hospitalcollaborator
- Guangzhou First People's Hospitalcollaborator
- First Affiliated Hospital Xi'an Jiaotong Universitycollaborator
- Xijing Hospital,FMMUcollaborator
Study Sites (1)
Beijing Anzhen Hospital
Beijing, Beijing Municipality, 100013, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Vice Chairman, Aortic Surgery Committee of Chinese Association of Cardiovascular Surgeons; President, Beijing Society for Thoracic and Cardiovascular Surgery; Director, Center for Aortic Surgery, Beijing Anzhen Hospital
Study Record Dates
First Submitted
August 25, 2025
First Posted
September 2, 2025
Study Start
February 1, 2026
Primary Completion (Estimated)
December 30, 2027
Study Completion (Estimated)
February 28, 2028
Last Updated
December 15, 2025
Record last verified: 2025-09
Data Sharing
- IPD Sharing
- Will not share